Our previous in vivo studies confirmed that ICD-85, as an anticancer agent, was able to prevent further growth of breast tumors and expand the life expectancy of mice with breast cancer. Blood collection was carried out before, 1, 3, and 6 hours after ICD-85 injection. Sera were used to determinate the cardio and hepatic enzymes levels, including ALT, AST, LDH, CPK, and Ck-MB. Coagulation factors such as PT and PTT were also assayed. ECGs of all rabbits were recorded during the experiment. ECG results showed that the injection of 50 and 100 micro g/kg ICD-85 into healthy rabbits has no significant effect on heart function while the injection of 150 to 200 micro g/kg ICD-85 caused ECG wave changes and mild bradycardia without toxic effects on heart. After ICD-85 injection [concentrations below 100 micro g/kg] , no significant increase was observed in liver and cardiac enzymes [ALT, AST, LDH, CPK, and CK-MB] . However, the concentration of 150 micro g/kg and above caused a rise in the enzymes. Comparison of the PT and PTT before and after ICD-85 injection showed no significant clotting time at any concentrations below 200 micro g/kg. Based on the results obtained in the present study as well as our previous reports, ICD-85 at concentrations below 100 micro g/kg seems to have no significant effect on the serum enzymes as indicators of hepatotoxicity and cardiotoxicity in healthy rabbits. However, to confirm this conclusion, more detailed surveys on heart and liver is needed to be carried out